57976-57-5

Basic information

• Product Name: 3-Pyridin-3-ylaniline
• Synonyms: 3-PYRIDIN-3-YLANILINE;3-PYRIDIN-3-YL-PHENYLAMINE;AKOS BAR-2462;3-(3-Aminophenyl)pyridine;3-(Pyridin-3-yl)aniline 97%;3-(Pyridin-3-yl)benzenamine;3-(3-Pyridyl)aniline;3-(Pyridin-3-yl)aniline97%
• CAS NO: 57976-57-5
• Molecular Formula: C₁₁H₁₀N₂
• Molecular Weight: 170.21
• Product Categories: Amines and Anilines;Heterocycles
• Mol File: 57976-57-5.mol
• Article Data: 24

Chemical Properties

• Melting Point: 72-74
• Boiling Point: 0
• Flash Point: 204.357 °C
• Appearance: /
• Density: 1.133 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.85±0.11(Predicted)
• CAS DataBase Reference: 3-Pyridin-3-ylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridin-3-ylaniline(57976-57-5)
• EPA Substance Registry System: 3-Pyridin-3-ylaniline(57976-57-5)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 57976-57-5(Hazardous Substances Data)

Usage

General Description

3-Pyridin-3-ylaniline, also known as 3-(3-Pyridyl)aniline, is a chemical compound with the molecular formula C11H10N2. It consists of a pyridine ring and an aniline group connected by a 3-carbon linker. 3-Pyridin-3-ylaniline is commonly used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of various organic compounds and drugs, due to its unique structure and reactivity. Additionally, this compound may be utilized in the preparation of heterocyclic molecules and as a starting material in the production of specialty chemicals. Overall, 3-Pyridin-3-ylaniline is a versatile chemical with diverse applications in the fields of chemistry, medicine, and materials science.

InChI:InChI=1/C11H10N2/c12-11-5-1-3-9(7-11)10-4-2-6-13-8-10/h1-8H,12H2

Upstream product

• 63843-12-9 4-(1-pyridin-3-yl-vinyl)-morpholine 
• 591-19-5 m-Bromoaniline 
• 626-60-8 3-Chloropyridine 
• 108-42-9 3-chloro-aniline 
• 59020-10-9 3-(tributylstannyl)pyridine 
• 220565-63-9 pyridin-3-ylzinc(II) bromide 
• 626-01-7 3-Iodoaniline 
• 645-00-1 m-iodonitrobenzene 
• 1692-25-7 3-pyridylboronic acid 
• 4282-50-2 3-(3-nitrophenyl)pyridine 
• 63843-23-2 3-(3-Pyridinyl)-2-cyclohexen-1-one oxime 
• 63843-14-1 3-(3-pyridinyl)-2-cyclohexen-1-one 
• 350-03-8 methyl-3-pyridylketone 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 842127-52-0 compound 30 
• 617683-52-0 N-(6-methyl-2-nitropyridin-3-yl)-N-[3-(pyridin-3-yl)phenyl]amine 
• 460750-67-8 (6,7-diethoxy-quinazolin-4-yl)-(3-pyridin-3-yl-phenyl)-amine hydrochloride 
• 1071925-73-9 N-(3-(pyridin-3-yl)phenyl)-4-(pyridin-3-yl)benzamide 
• 1071925-75-1 N-(3-(pyridin-3-yl)phenyl)-4-(pyrimidin-5-yl) benzamide 
• 1071925-74-0 N-(3-(pyridin-3-yl)phenyl)-4-(pyridin-4-yl)benzamide 
• 769160-04-5 N-(3-(3-pyridyl)phenyl)-4-bromo-2-nitroaniline 
• 40036-03-1 2-[(3-Pyridin-3-yl-phenylamino)-methylene]-malonic acid diethyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS

The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution

Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CP55,940-induced intracellular calcium mobilization and [35S]GTP-γ-S binding while enhancing [3H]CP55,940 binding to the CB1 receptor. Structure-activity relationship studies revealed that the pyridinyl ring of 2 could be replaced by other aromatic rings and the pyrrolidinyl ring is not required for CB1 allosteric modulation. 34 (RTICBM-74) had similar potencies as 2 in all in vitro assays but showed significantly improved metabolic stability to rat liver microsomes. More importantly, 34 was more effective than 2 in attenuating the reinstatement of extinguished cocaine-seeking behavior in rats, demonstrating the potential of this diarylurea series as promising candidates for the development of relapse treatment of cocaine addiction.